Association Between Low-Dose Aspirin and Uric Acid in the Elderly: An Observational Retrospective Cross-Sectional Study

References

• Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet. 2016;387(10015):251–272.
   PubMed Web of Science ®Google Scholar
• Mortality GBD. Causes of Death C. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–171.
   PubMed Web of Science ®Google Scholar
• Multidisciplinary Expert Task Force on H, Related D. Chinese multidisciplinary expert consensus on the diagnosis and treatment of hyperuricemia and related diseases. Chin Med J (Engl). 2017;130(20):2473–2488.
   PubMed Web of Science ®Google Scholar
• Li M, Hu X, Fan Y, et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. Sci Rep. 2016;6:19520.
   PubMed Web of Science ®Google Scholar
• Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000;283(18):2404–2410.
   PubMed Web of Science ®Google Scholar
• Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med. 2009;266(6):558–570.
   PubMed Web of Science ®Google Scholar
• Ndrepepa G. Uric acid and cardiovascular disease. Clin Chim Acta. 2018;484:150–163.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS. Uric acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis. 2018;71(3):362–370.
   PubMed Web of Science ®Google Scholar
• Borghi C, Rosei EA, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33(9):1729–1741; discussion 1741.
   PubMed Web of Science ®Google Scholar
• Maloberti A, Giannattasio C, Bombelli M, et al. Hyperuricemia and risk of cardiovascular outcomes: the experience of the URRAH (Uric Acid Right for Heart Health) Project. High Blood Press Cardiovasc Prev. 2020;27(2):121–128.
   PubMed Web of Science ®Google Scholar
• Russo E, Viazzi F, Pontremoli R, et al. Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. J Nephrol. 2021.
   Web of Science ®Google Scholar
• Maloberti A, Bombelli M, Facchetti R, et al. Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study. J Hypertens. 2021;39(2):333–340.
   PubMed Web of Science ®Google Scholar
• Ben Salem C, Slim R, Fathallah N, Hmouda H. Drug-induced hyperuricaemia and gout. Rheumatology (Oxford). 2017;56(5):679–688.
   PubMed Web of Science ®Google Scholar
• Ra T. Primer on the rheumatic diseases.11th ed. Atlanta: Arthritis Foundation. Epidemiol Pathol Pathogenesis. 1997;230-243.
   Google Scholar
• Li M, Li X, Liu Y, et al. Relationship between serum bilirubin levels s and the progression of renal function in patients with chronic kidney disease and hyperuricemia. Clin Chim Acta. 2018;486:156–161.
   PubMed Web of Science ®Google Scholar
• Task Force on Chinese Guidelines for the Prevention of Cardiovascular D, Editorial Board of Chinese Journal of C. [Chinese guidelines for the prevention of cardiovascular diseases(2017)]. Zhonghua Xin Xue Guan Bing Za Zhi. 2018;46(1):10–25.
   PubMedGoogle Scholar
• Maruhashi T, Hisatome I, Kihara Y, Higashi Y. Hyperuricemia and endothelial function: from molecular background to clinical perspectives. Atherosclerosis. 2018;278:226–231.
   PubMed Web of Science ®Google Scholar
• Muhammad Mansyur Romi NA, Tranggono U, Wahyu Setyaningsih WA, Ratna Sari DC. Uric acid causes kidney injury through inducing fibroblast expansion, Endothelin-1 expression, and inflammation. BMC Nephrol. 2017;18(1):326.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Neogi T, Chen C, Chaisson C, Hunter DJ, Choi H. Low-dose aspirin use and recurrent gout attacks. Ann Rheum Dis. 2014;73(2):385–390.
   PubMed Web of Science ®Google Scholar
• Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum. 2000;43(1):103–108.
   PubMed Web of Science ®Google Scholar
• Akinwusi PO, Oluyombo R, Ogunro PS, Adeniji AO, Okunola OO, Ayodele OE. Low dose aspirin therapy and renal function in elderly patients. Int J Gen Med. 2013;6:19–24.
   PubMedGoogle Scholar
• Zhang P, Wang H, Chen XH, Liang WY, Liu WW, Liu ML. Effect of low-dose aspirin on serum uric acid levels in Chinese individuals over 60: subanalysis of a multicentre randomized clinical trial. Eur Rev Med Pharmacol Sci. 2020;24(5):2719–2724.
   PubMed Web of Science ®Google Scholar
• Segal R, Lubart E, Leibovitz A, et al. Early and late effects of low-dose aspirin on renal function in elderly patients. Am J Med. 2003;115(6):462–466.
   PubMed Web of Science ®Google Scholar
• Segal R, Lubart E, Leibovitz A, Iaina A, Caspi D. Renal effects of low dose aspirin in elderly patients. Isr Med Assoc J. 2006;8(10):679–682.
   PubMed Web of Science ®Google Scholar
• Ali H, Shaaban A, Murtaza A, Howell LE, Ahmed A. Effect of long-term, low-dose aspirin therapy on renal graft function. Exp Clin Transplant. 2017;15(4):400–404.
   PubMed Web of Science ®Google Scholar
• Goicoechea M, de Vinuesa SG, Quiroga B, et al. Aspirin for primary prevention of cardiovascular disease and renal disease progression in chronic kidney disease patients: a multicenter randomized clinical trial (AASER Study). Cardiovasc Drugs Ther. 2018;32(3):255–263.
   PubMed Web of Science ®Google Scholar
• El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4. Br J Pharmacol. 2008;155(7):1066–1075.
   PubMed Web of Science ®Google Scholar
• Massimi I, Ciuffetta A, Temperilli F, et al. Multidrug resistance Protein-4 influences aspirin toxicity in human cell line. Mediators Inflamm. 2015;2015:607957.
   PubMed Web of Science ®Google Scholar
• Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984;311(19):1206–1211.
   PubMed Web of Science ®Google Scholar
• Purkerson ML, Joist JH, Yates J, Valdes A, Morrison A, Klahr S. Inhibition of thromboxane synthesis ameliorates the progressive kidney disease of rats with subtotal renal ablation. Proc Natl Acad Sci U S A. 1985;82(1):193–197.
   PubMed Web of Science ®Google Scholar
• Pierucci A, Simonetti BM, Pecci G, et al. Improvement of renal function with selective thromboxane antagonism in lupus nephritis. N Engl J Med. 1989;320(7):421–425.
   PubMed Web of Science ®Google Scholar
• Luepker RV, Oldenburg NC, Misialek JR, et al. Aspirin use and misuse for the primary prevention of cardiovascular diseases. Am J Prev Med. 2021.
   PubMed Web of Science ®Google Scholar
• Patrono C, Baigent C. Role of aspirin in primary prevention of cardiovascular disease. Nat Rev Cardiol. 2019;16(11):675–686.
   PubMed Web of Science ®Google Scholar